Tolerability of a Salmeterol Xinafoate/Fluticasone Propionate Hydrofluoroalkane Metered-Dose Inhaler in Adolescent and Adult Patients with Persistent Asthma: A 52-Week, Open-Label, Stratified, Parallel-Group, Multicenter Study

Clinical Therapeutics

Volumn 29, Issue 7, 2007, Pages 1390-1402

  Cowie, Robert L ^a   Boulet, Louis Philippe ^b   Keith, Paul K ^c   Scott Wilson, Catherine A ^d   House, Karen W ^d   Dorinsky, Paul M ^d  

^a UNIVERSITY OF CALGARY   (Canada)

^b LAVAL UNIVERSITY   (Canada)

^c MCMASTER UNIVERSITY   (Canada)

^d GLAXOSMITHKLINE   (United States)

Author keywords

fluticasone propionate; long term tolerability; metered dose inhaler; non chlorofluorocarbon hydrofluoroalkane 134a propellant; persistent asthma; salmeterol

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; BUDESONIDE; CORTICOSTEROID DERIVATIVE; FLUTICASONE PROPIONATE; FLUTICASONE PROPIONATE PLUS SALMETEROL; LONG ACTING DRUG; SALBUTAMOL; SHORT ACTING DRUG;

ADOLESCENT; ADULT; ALLERGY; ANXIETY; ARTHRALGIA; ARTICLE; ASTHMA; BONE PAIN; BRONCHITIS; CANDIDIASIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DEPRESSION; DIARRHEA; DOSE RESPONSE; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPHONIA; EAR INFECTION; FEMALE; FEVER; FORCED EXPIRATORY VOLUME; GASTROENTERITIS; GASTROINTESTINAL PAIN; GASTROINTESTINAL SYMPTOM; HEADACHE; HEART VENTRICLE EXTRASYSTOLE; HOARSENESS; HUMAN; HYDROCORTISONE URINE LEVEL; HYPERGLYCEMIA; LABORATORY TEST; LARYNGITIS; LIP DISEASE; LIP EDEMA; LONG TERM CARE; LOWER RESPIRATORY TRACT INFECTION; MAJOR CLINICAL STUDY; MALE; METERED DOSE INHALER; MIGRAINE; MONOTHERAPY; MULTICENTER STUDY; MUSCLE SORENESS; MYALGIA; NAUSEA AND VOMITING; NOSE CONGESTION; NOSE INFECTION; PEAK EXPIRATORY FLOW; PREMENSTRUAL SYNDROME; RANDOMIZED CONTROLLED TRIAL; RHEUMATOID ARTHRITIS; RHINITIS; SCHOOL CHILD; SIDE EFFECT; SINUSITIS; THORAX PAIN; THROAT IRRITATION; THRUSH; TOOTH PAIN; TREATMENT OUTCOME; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; VIRUS INFECTION;

EID: 34548317546     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2007.07.021     Document Type: Article

References (20)

1. Global Initiative for Asthma. GINA Report, Global Strategy for Asthma Management and Prevention [GINA Web site]. Available at:. http://www.ginasthma.org Accessed February 7, 2007
2. FitzGerald J., Boulet L., McIvor I., et al. Asthma control in Canada remains suboptimal: The Reality of Asthma Control (TRAC) study. Can Respir J 13 (2006) 253-259
3. Chambers C., Markson L., Diamond J., et al. Health beliefs and compliance with inhaled corticosteroids by asthmatic patients in primary care practices. Respir Med 93 (1999) 88-94
4. Apter A., Reisine S., Affleck G., et al. Adherence with twice-daily dosing of inhaled steroids. Socioeconomic and health-belief differences. Am J Respir Crit Care Med 157 (1998) 1810-1817
5. Kavuru M., Melamed J., Gross G., et al. Salmeterol and fluticasone propionate combined in a new powder inhalation device for the treatment of asthma: A randomized, double-blind, placebo-controlled trial. J Allergy Clin Immunol 105 (2000) 1108-1116
6. Shapiro G., Lumry W., Wolfe J., et al. Combined salmeterol 50 microg and fluticasone propionate 250 microg in the diskus device for the treatment of asthma. AmJ Respir Crit Care Med 161 (2000) 527-534
7. Aubier M., Pieters W., Schlosser N., and Steinmetz K. Salmeterol/fluticasone propionate (50/500 microg) in combination in a Diskus inhaler (Seretide) is effective and safe in the treatment of steroid-dependent asthma. Respir Med 93 (1999) 876-884
8. Bateman E., Britton M., Camllo J., et al. Salmeterol/fluticasone combination inhaler. A new, effective and well tolerated treatment for asthma. Clin Drug Invest 16 (1998) 193-201
9. Chapman K., Ringdal N., Backer V., et al. Salmeterol and fluticasone propionate (50/250 microg) administered via combination Diskus inhaler: As effective as when given via separate Diskus inhalers. Can RespirJ 6 (1999) 45-51
10. Leach C. The CFC to HFA transition and its impact on pul-onary drug development. Respir Care 50 (2005) 1201-1208
11. World Medical Association Declaration of Helsinki. Recommendations Guiding Medical Doctors in Biomedical Research Involving Human Patients [WMA Web site] (1996), WMA, Republic of South Africa. http://www.wma.net Accessed February 7, 2007
12. European Agency for the Evaluation of Medicinal Products, International Conference on Harmonisation-World Health Organization. Guideline for Good Clinical Practice [EMEA Web site]. ICH Topic E6 (2002), WHO, Geneva, Switzerland. http://www.emea.eu.int Accessed February 7, 2007
13. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease (COPD) and asthma. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, November 1986. Am Rev Respir Dis 136 (1987) 225-244
14. Polgar G., and Promadhat V. Pulmonary Function Testing in Children: Techniques and Standards (1971), WB Saunders, Philadelphia, Pa
15. Standardization of lung function tests as contained in the report of the working party of the European Community for Coal and Steel. Eur Respir J. 6 Suppl 16 (1993) 5-40
16. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH Harmonised Tripartite Guideline. The extent of population exposure to assess clinical safety for drugs intended for long-term treatment for non-life-threatening conditions. El. October 1994. Published in the Federal Register Vol. 60 (March 1, 1995) 11270
17. Lundback B., Ronmark E., Lindberg A., et al. Control of mild to moderate asthma over 1-year with the combination ofsalmeterol and fluticasone propionate. RespirMed 100 (2006) 2-10
18. Nelson H., Wolfe J., Gross G., et al. Efficacy and safety of fluticasone propionate 44 microg/salmeterol 21 microg administered in a hydrofluoroalkane metered-dose in-haler as an initial asthma maintenance treatment. Ann Allergy Asthma Immunol 91 (2003) 263-269
19. Pearlman D., Peden D., Condemi J., et al. Efficacy and safety of fluticasone propionate/salmeterol HFA 134A MDI in patients with mild-to-moderate persistent asthma. J Asthma 41 (2004) 797-806
20. Nathan I., Rooklin A., Schoaf L., et al. Efficacy and tolerability of fluticasone propionate/salmeterol administered twice daily via hydrofluoroalkane 134a metered-dose inhaler in adolescent and adult patients with persistent asthma: A randomized, double-blind, placebo-controlled, 12-week study. Clin Ther 28 (2006) 73-85